Navigation Links
GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
Date:11/11/2013

eading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.

Forward-looking statements

This news release may contain forward-looking statements that reflect GWs current expectations regarding future events, including statements regarding our clinical goals, our plans for a clinical trial, the ability to conduct clinical trials sufficient to achieve positive completion, and the therapeutic and commercial value of the company's compounds. To the degree we are able to conduct clinical trials, we may have difficulty in enrolling candidates for testing and we may not be able to achieve the desired results. Forward-looking statements involve risks and uncertainties.  Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of the GW's research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex® and other products by consumer and medical professionals. A further list and description of risks, uncertainties and other risks associated with an investment in GW can be found in GW's filings with the U.S. Securities and Exchange Commission, including the prospectus related to the NASDAQ offering filed by GW with the SEC on May 1, 2013. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result o
'/>"/>

SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
(Date:3/4/2015)... NEWTOWN, Pa. , March 4, 2015 ... trials services and technology provider, today announced ... and 10 countries convened at its annual ... Spain to discuss the use ... development challenges. BioClinica,s eClinical technologies include: the ...
(Date:3/4/2015)... Follow us on LinkedIn ... fastest growing technologies in the life sciences industry. Growing ... driving growth in nucleic acid detection technologies like qPCR ... expressions will continue to benefit the qPCR and dPCR ... from pharma, biotech, food & beverage to animal feed, ...
(Date:3/4/2015)... -- Lancée par l,Assistance Publique ... en décembre 2011, l,étude collaborative française randomisée et ...   l es microsphères en résine marquées ... carcinome hépatocellulaire avancé, a recruté plus de 400 ... ; les résultats sont attendus fin 2016.   ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... of partner clinics, fits dozens ... ... /PRNewswire/ - Touch,Bionics, developer of the world,s first commercially available bionic ... Currently basing U.S. operations out of Boston, MA, this announcement,follows the ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading developer ... treatment systems, today announced that the company,will host ... on Tuesday,February 12, 2008 at 9:00 a.m. ET., ... Officer Michael Davin and,Executive Vice President and Chief ...
... Ga. and RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial ... signed an,agreement under which Merial will screen a Chimerix ... of this agreement, Merial has an,option to negotiate a ... use., "This collaboration with Chimerix provides us with ...
Cached Biology Technology:Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 2Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 3Touch Bionics expands U.S. presence to meet demand for i-LIMB Hand 4Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12 2Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/23/2015)... OXFORD, Conn. , Feb. 23, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62114357 for ... With this patent, NXT-ID introduces a new groundbreaking payment ... and the payment account may only be accessed if ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
... Researchers at Huntsman Cancer Institute (HCI) at the University ... often deadly bone cancer that typically afflicts children and young ... tumors with high levels of a protein known as GSTM4, ... published online today in the journal Oncogene . ...
... of Oceanography at UC San Diego and their colleagues ... structure of a naturally produced, ocean-based compound that is ... cells. The findings are reported in the Aug. ... Biology by principal co-investigators William Gerwick, professor of ...
... (August 28, 2009)The American Phytopathological Society (APS) is proud ... Scientist, is the recipient of the 2009 Plant Pathology ... Green Menace," published in the March 13, 2008, issue ... Green Menace," Callaway discussed the citrus disease huanglongbinga bacterial ...
Cached Biology News:New hope for deadly childhood bone cancer 2Marine biomedicine researchers decode structure of promising sea compound 2Ewen Callaway named 2009 APS Plant Pathology Journalism awardee 2
Anti-MMP-19 (RASI), carboxy terminal region; rabbit host...
Rabbit anti MMP-13, Hinge Region MMP-13 Hinge Region...
Rabbit polyclonal to ATF4 (phospho S245) ( Abpromise for all tested applications). Antigen: Synthetic phosphopeptide derived from human ATF4 around the phosphorylation site of Serine 245. En...
Evolutionarily conserved signaling intermediate in Toll pathway...
Biology Products: